Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Trials ; 19(1): 525, 2018 Sep 27.
Article in English | MEDLINE | ID: mdl-30261933

ABSTRACT

BACKGROUND: There is a widely recognized need for more pragmatic trials that evaluate interventions in real-world settings to inform decision-making by patients, providers, and health system leaders. Increasing availability of electronic health records, centralized research ethics review, and novel trial designs, combined with support and resources from governments worldwide for patient-centered research, have created an unprecedented opportunity to advance the conduct of pragmatic trials, which can ultimately improve patient health and health system outcomes. Such trials raise ethical issues that have not yet been fully addressed, with existing literature concentrating on regulations in specific jurisdictions rather than arguments grounded in ethical principles. Proposed solutions (e.g. using different regulations in "learning healthcare systems") are speculative with no guarantee of improvement over existing oversight procedures. Most importantly, the literature does not reflect a broad vision of protecting the core liberty and welfare interests of research participants. Novel ethical guidance is required. We have assembled a team of ethicists, trialists, methodologists, social scientists, knowledge users, and community members with the goal of developing guidance for the ethical design and conduct of pragmatic trials. METHODS: Our project will combine empirical and conceptual work and a consensus development process. Empirical work will: (1) identify a comprehensive list of ethical issues through interviews with a small group of key informants (e.g. trialists, ethicists, chairs of research ethics committees); (2) document current practices by reviewing a random sample of pragmatic trials and surveying authors; (3) elicit views of chairs of research ethics committees through surveys in Canada, UK, USA, France, and Australia; and (4) elicit views and experiences of community members and health system leaders through focus groups and surveys. Conceptual work will consist of an ethical analysis of identified issues and the development of new ethical solutions, outlining principles, policy options, and rationales. The consensus development process will involve an independent expert panel to develop a final guidance document. DISCUSSION: Planned output includes manuscripts, educational materials, and tailored guidance documents to inform and support researchers, research ethics committees, journal editors, regulators, and funders in the ethical design and conduct of pragmatic trials.


Subject(s)
Ethics Committees, Research/ethics , Ethics, Research , Pragmatic Clinical Trials as Topic/ethics , Research Design , Consensus , Consensus Development Conferences as Topic , Ethics Committees, Research/standards , Humans , Interdisciplinary Communication , Multicenter Studies as Topic , Practice Guidelines as Topic , Pragmatic Clinical Trials as Topic/methods , Pragmatic Clinical Trials as Topic/standards , Research Design/standards , Review Literature as Topic , Stakeholder Participation
2.
Trials ; 19(1): 334, 2018 Jun 25.
Article in English | MEDLINE | ID: mdl-29941000

ABSTRACT

BACKGROUND: Quality and service improvement (QSI) research employs a broad range of methods to enhance the efficiency of healthcare delivery. QSI research differs from traditional healthcare research and poses unique ethical questions. Since QSI research aims to generate knowledge to enhance quality improvement efforts, should it be considered research for regulatory purposes? Is review by a research ethics committee required? Should healthcare providers be considered research participants? If participation in QSI research entails no more than minimal risk, is consent required? The lack of consensus on answers to these questions highlights the need for ethical guidance. MAIN BODY: Three distinct approaches to classifying QSI research in accordance with existing ethical principles and regulations can be found in the literature. In the first approach, QSI research is viewed as distinct from other types of healthcare research and does not require regulation. In the second approach, QSI research falls within regulatory guidelines but is exempt from research ethics committee review. In the third approach, QSI research is deemed to be part of the learning healthcare system and, as such, is subject to a different set of ethical principles entirely. In this paper, we critically assess each of these views. CONCLUSION: While none of these approaches is entirely satisfactory, we argue that use of the ethical principles governing research provides the best means of addressing the numerous questions posed by QSI research.


Subject(s)
Delivery of Health Care/ethics , Ethics Committees, Research , Health Services Research/ethics , Quality Improvement/ethics , Quality Indicators, Health Care/ethics , Research Design , Delivery of Health Care/standards , Health Services Research/standards , Humans , Policy Making , Quality Improvement/standards , Quality Indicators, Health Care/standards , Research Design/standards
3.
J Med Ethics ; 44(9): 593-598, 2018 09.
Article in English | MEDLINE | ID: mdl-29703860

ABSTRACT

The ethics of the Flexibility In duty hour Requirements for Surgical Trainees (FIRST) trial have been vehemently debated. Views on the ethics of the FIRST trial range from it being completely unethical to wholly unproblematic. The FIRST trial illustrates the complex ethical challenges posed by cluster randomised trials (CRTs) of policy interventions involving healthcare professionals. In what follows, we have three objectives. First, we critically review the FIRST trial controversy, finding that commentators have failed to sufficiently identify and address many of the relevant ethical issues. The 2012 Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials provides researchers and research ethics committees with specific guidance for the ethical design and conduct of CRTs. Second, we aim to demonstrate how the Ottawa Statement provides much-needed clarity to the ethical issues in the FIRST trial, including: research participant identification; consent requirements; gatekeeper roles; benefit-harm analysis and identification of vulnerable participants. We nonetheless also find that the FIRST trial raises ethical issues not adequately addressed by the Ottawa Statement. Hence, third and finally, we raise important questions requiring further ethical analysis and guidance, including: Does clinical equipoise apply to policy interventions with little or no evidence-base? Do healthcare providers have an obligation to participate in research? Does the power-differential in certain healthcare settings render healthcare providers vulnerable to duress and coercion to participant in research? If so, what safeguards might be implemented to protect providers, while allowing important research to proceed?


Subject(s)
Ethics, Research , Internship and Residency/organization & administration , Personnel Staffing and Scheduling/ethics , Randomized Controlled Trials as Topic/ethics , Ethics Committees, Research/ethics , Humans , Informed Consent/ethics , Internship and Residency/ethics , Internship and Residency/standards , Research Design , Research Personnel/ethics , Research Subjects/psychology , Risk Assessment
4.
Kennedy Inst Ethics J ; 28(1): 85-118, 2018.
Article in English | MEDLINE | ID: mdl-29628452

ABSTRACT

The SUPPORT trial highlights ethical challenges raised by comparative effectiveness randomized controlled trials (ceRCTs) involving one or more usual care interventions. Debate about the SUPPORT trial has focused on whether study interventions posed "reasonably foreseeable risks" to enrolled infants and, thereby, reflects a preoccupation with U.S. regulations. As ceRCTs are conducted globally, our analysis of the SUPPORT trial is grounded in internationally accepted ethical principles. We argue that the central ethical issue raised by the SUPPORT trial is the following: should the SUPPORT trial interventions be conceptualized as practice, or research? The answer to this question has important implications for "downstream" ethical requirements-including whether the usual care interventions in ceRCTs require research ethics committee review, undergo harm-benefit analysis, and are included in informed consent documents-and it is antecedent to the development of ethical guidance for ceRCTs.


Subject(s)
Comparative Effectiveness Research/ethics , Oxygen Inhalation Therapy/adverse effects , Oxygen Inhalation Therapy/methods , Pragmatic Clinical Trials as Topic/ethics , Humans , Infant, Newborn , Infant, Premature , Informed Consent , Oximetry , Oxygen/blood , Respiratory Distress Syndrome, Newborn/mortality , Respiratory Distress Syndrome, Newborn/therapy , Retinopathy of Prematurity/etiology , Retinopathy of Prematurity/prevention & control
5.
BMC Med Ethics ; 19(1): 14, 2018 02 27.
Article in English | MEDLINE | ID: mdl-29482537

ABSTRACT

BACKGROUND: Pragmatic randomized controlled trials (RCTs) are designed to evaluate the effectiveness of interventions in real-world clinical conditions. However, these studies raise ethical issues for researchers and regulators. Our objective is to identify a list of key ethical issues in pragmatic RCTs and highlight gaps in the ethics literature. METHODS: We conducted a scoping review of articles addressing ethical aspects of pragmatic RCTs. After applying the search strategy and eligibility criteria, 36 articles were included and reviewed using content analysis. RESULTS: Our review identified four major themes: 1) the research-practice distinction; 2) the need for consent; 3) elements that must be disclosed in the consent process; and 4) appropriate oversight by research ethics committees. 1) Most authors reject the need for a research-practice distinction in pragmatic RCTs. They argue that the distinction rests on the presumptions that research participation offers patients less benefit and greater risk than clinical practice, but neither is true in the case of pragmatic RCTs. 2) Most authors further conclude that pragmatic RCTs may proceed without informed consent or with simplified consent procedures when risks are low and consent is infeasible. 3) Authors who endorse the need for consent assert that information need only be disclosed when research participation poses incremental risks compared to clinical practice. Authors disagree as to whether randomization must be disclosed. 4) Finally, all authors view regulatory oversight as burdensome and a practical impediment to the conduct of pragmatic RCTs, and argue that oversight procedures ought to be streamlined when risks to participants are low. CONCLUSION: The current ethical discussion is framed by the assumption that the function of research oversight is to protect participants from risk. As pragmatic RCTs commonly involve usual care interventions, the risks may be minimal. This leads many to reject the research-practice distinction and question the need for informed consent. But the function of oversight should be understood broadly as protecting the liberty and welfare interest of participants and promoting public trust in research. This understanding, we suggest, will focus discussion on questions about appropriate ethical review for pragmatic RCTs.


Subject(s)
Bioethical Issues , Biomedical Research/ethics , Ethical Review , Informed Consent , Randomized Controlled Trials as Topic/ethics , Disclosure , Ethics Committees, Research , Ethics, Research , Humans
6.
Bioorg Med Chem ; 20(14): 4443-50, 2012 Jul 15.
Article in English | MEDLINE | ID: mdl-22698784

ABSTRACT

We describe the design, synthesis and fluorescence profiles of new self-calibrating viscosity dyes in which a coumarin (reference fluorophore) has been covalently linked with a molecular rotor (viscosity sensor). Characterization of their fluorescence properties was made with separate excitation of the units and through resonance energy transfer from the reference to the sensor dye. We have modified the linker and the substitution of the rotor in order to change the hydrophilicity of these probes thereby altering their subcellular localization. For instance, hydrophilic dye 12 shows a homogeneous distribution inside the cell and represents a suitable probe for viscosity measurements in the cytoplasm.


Subject(s)
Fluorescence Resonance Energy Transfer , Fluorescent Dyes/chemistry , Thiophenes/chemistry , Calibration , Cell Line, Tumor , Cell Membrane/metabolism , Coumarins/chemistry , Fluorescence Resonance Energy Transfer/standards , Fluorescent Dyes/analysis , Fluorescent Dyes/chemical synthesis , HeLa Cells , Humans , Hydrophobic and Hydrophilic Interactions , Microscopy, Confocal , Viscosity
SELECTION OF CITATIONS
SEARCH DETAIL
...